- Home
- AEP vs ALNY Comparison
AEP vs ALNY Comparison
Compare AEP & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEP
- ALNY
- Stock Information
- Founded
- AEP 1906
- ALNY 2002
- Country
- AEP United States
- ALNY United States
- Employees
- AEP N/A
- ALNY N/A
- Industry
- AEP Electric Utilities: Central
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- AEP Utilities
- ALNY Health Care
- Exchange
- AEP Nasdaq
- ALNY Nasdaq
- Market Cap
- AEP 61.0B
- ALNY 60.7B
- IPO Year
- AEP N/A
- ALNY 2004
- Fundamental
- Price
- AEP $122.32
- ALNY $463.36
- Analyst Decision
- AEP Hold
- ALNY Strong Buy
- Analyst Count
- AEP 14
- ALNY 27
- Target Price
- AEP $117.93
- ALNY $466.46
- AVG Volume (30 Days)
- AEP 3.5M
- ALNY 1.0M
- Earning Date
- AEP 10-29-2025
- ALNY 10-30-2025
- Dividend Yield
- AEP 3.23%
- ALNY N/A
- EPS Growth
- AEP 37.44
- ALNY N/A
- EPS
- AEP 6.83
- ALNY N/A
- Revenue
- AEP $21,257,000,000.00
- ALNY $2,461,963,000.00
- Revenue This Year
- AEP $8.17
- ALNY $60.04
- Revenue Next Year
- AEP $6.03
- ALNY $40.69
- P/E Ratio
- AEP $17.87
- ALNY N/A
- Revenue Growth
- AEP 8.44
- ALNY 5.01
- 52 Week Low
- AEP $89.91
- ALNY $205.87
- 52 Week High
- AEP $122.79
- ALNY $495.55
- Technical
- Relative Strength Index (RSI)
- AEP 71.12
- ALNY 49.33
- Support Level
- AEP $114.67
- ALNY $456.90
- Resistance Level
- AEP $122.79
- ALNY $485.36
- Average True Range (ATR)
- AEP 1.71
- ALNY 16.80
- MACD
- AEP 0.18
- ALNY -1.23
- Stochastic Oscillator
- AEP 94.17
- ALNY 33.70
About AEP American Electric Power Company Inc.
American Electric Power is one of the largest regulated utilities in the United States, providing electricity generation, transmission, and distribution to more than 5 million customers in 11 states. About 42% of AEP's of capacity is coal, with the remainder from a mix of natural gas (27%), renewable energy and hydro (21%), nuclear (8%), and demand response (2%). Vertically integrated utilities, transmission and distribution, and generation and marketing support earnings.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.